Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MGI Pharma completes acquisition of Guilford Pharmaceuticals
Under the terms of the acquisition all shares of Guilford were exchanged for 5.3 million shares of MGI Pharma stock plus $53.9 million in cash, which represents $3.75
Under the terms of the acquisition all shares of Guilford were exchanged for 5.3 million shares of MGI Pharma stock plus $53.9 million in cash, which represents $3.75
The parties anticipate the collaboration will initially focus on vascular, orthopedic and general surgery indications. Under the terms of the agreement, Angiotech will make an upfront license execution
Anthim was granted fast track status by the FDA on May 6th 2005, and this study will begin in the coming weeks. The company has also initiated manufacturing
Approximately 13.6 million adults in the US suffer from rosacea. It affects primarily the face and is characterized by the appearance of inflammatory lesions. The NDA submission was
Danazol is a generic version of Danocrine marketed by Sanofi-Aventis. It represses a sex hormone called gonadotropin, and is indicated for the treatment of uterine tissue growing outside
A recent study has found that double-stranded RNA (dsRNA), such as Ampligen, increases the effectiveness of the influenza vaccine by more than 300% and Ampligen may also convey
pSivida said that the acquisition would be funded through the issue of approximately 16 million pSivida shares to Control Delivery Systems stockholders, representing approximately 40% of the combined
FM-VP4 is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drugs. FM-VP4 has demonstrated significant cholesterol-lowering and anti-atherosclerotic properties in pre-clinical studies. The cardiovascular market represents a
Under the terms of the agreement, Allergan will license to GSK all clinical development and commercial rights to Botox in Japan and China, markets in which GSK has
Boots investors will own 50.2% of the new company, which will be called Alliance Boots, and shareholders of Alliance UniChem will hold the rest. Under terms of their